# OptiMATe (NCT04931368)

> OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma

No report yet. It can be ordered.

- Drugs tested: MATRix
- Indication: newly diagnosed primary CNS lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04931368
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Klinikum Stuttgart
- Conditions: Primary Central Nervous System Lymphoma
- Interventions: Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix; Control intervention: four courses of MATRix
- Enrollment: 331
- Primary outcome: Event-free survival (EFS)

## Indexed commentary on OptiMATe so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 7 posts on X
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=optimate-nct04931368

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04931368", "email": "<work email>"}; the inbox owner confirms by the emailed link.